Response of Degarelix treatment in human prostate cancer monitored by HR-MAS 1H NMR spectroscopy
Crossref DOI link: https://doi.org/10.1007/s11306-016-1055-0
Published Online: 2016-06-30
Published Print: 2016-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Madhu, Basetti http://orcid.org/0000-0001-5844-856X
Shaw, Greg L.
Warren, Anne Y.
Neal, David E.
Griffiths, John R.
Funding for this research was provided by:
Cancer Research UK (C14303/A17197)
License valid from 2016-06-30